Evidence map›Paper›PMID 34830868›Full record

ArticleCancers2021

Targeted Selected Reaction Monitoring Verifies Histology Specific Peptide Signatures in Epithelial Ovarian Cancer.

Leena Liljedahl, Johan Malmström, Björg Kristjansdottir, Sofia Waldemarson, Karin Sundfeldt

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Leena LiljedahlCREATE Health Translational Cancer Center, Department of Immunotechnology, Lund University, Medicon Village, 223 81 Lund, Sweden.
Johan MalmströmDepartment of Clinical Sciences, Lund University, BMC D13, 221 84 Lund, Sweden.ORCID 0000-0002-2889-7169
Björg KristjansdottirSahlgrenska Center for Cancer Research, Department of Obstetrics and Gynecology, Institute of Clinical Sciences, University of Gothenburg, 405 30 Gothenburg, Sweden.
Sofia WaldemarsonCREATE Health Translational Cancer Center, Department of Immunotechnology, Lund University, Medicon Village, 223 81 Lund, Sweden.
Karin SundfeldtSahlgrenska Center for Cancer Research, Department of Obstetrics and Gynecology, Institute of Clinical Sciences, University of Gothenburg, 405 30 Gothenburg, Sweden.
Lund University · SEUniversity of Gothenburg · SE

Funding

Cancera (LL, SW) not applicableMagnus Bergvall foundation (SW) Not applicableMrs Berta Kamprad´s Cancer Foundation (SW) Not applicableSwedish Cancer Foundation (KS) CAN 2018/384Swedish state under the agreement between the Swedish government and the county council, the ALF-agreement (KS) 70950The Lars Hierta Memorial Foundation (SW) not applicable
6 · The paper itself

Abstract

Epithelial ovarian cancer (OC) is a disease with high mortality due to vague early clinical symptoms. Benign ovarian cysts are common and accurate diagnosis remains a challenge because of the molecular heterogeneity of OC. We set out to investigate whether the disease diversity seen in ovarian cyst fluids and tumor tissue could be detected in plasma. Using existing mass spectrometry (MS)-based proteomics data, we constructed a selected reaction monitoring (SRM) assay targeting peptides from 177 cancer-related and classical proteins associated with OC. Plasma from benign, borderline, and malignant ovarian tumors were used to verify expression (

Indexed as

biomarkersearly-stage diagnosticsepithelial ovarian cancer (OC)proteomicstargeted selected reaction monitoring (SRM)

Identifiers

PMID34830868
PMCPMC8616310
OpenAlexW3213343963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.